Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 274,963,680
  • Shares Outstanding, K 2,535,396
  • Annual Sales, $ 48,704 M
  • Annual Income, $ 13,049 M
  • 60-Month Beta 0.38
  • Price/Sales 5.60
  • Price/Cash Flow 14.69
  • Price/Book 6.12
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 22.42% ( +1.12%)
  • Historical Volatility 21.21%
  • IV Percentile 28%
  • IV Rank 20.70%
  • IV High 33.74% on 11/30/21
  • IV Low 19.47% on 03/25/22
  • Put/Call Vol Ratio 1.51
  • Today's Volume 50,663
  • Volume Avg (30-Day) 41,932
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 609,957
  • Open Int (30-Day) 611,127

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 1.54
  • Number of Estimates 6
  • High Estimate 1.73
  • Low Estimate 1.49
  • Prior Year 1.80
  • Growth Rate Est. (year over year) -14.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.33 +11.43%
on 11/11/22
108.90 -0.41%
on 11/28/22
+7.68 (+7.62%)
since 10/28/22
3-Month
84.52 +28.31%
on 09/21/22
108.90 -0.41%
on 11/28/22
+19.19 (+21.50%)
since 08/26/22
52-Week
71.50 +51.68%
on 12/07/21
108.90 -0.41%
on 11/28/22
+29.29 (+37.00%)
since 11/26/21

Most Recent Stories

More News
Should Invesco Dow Jones Industrial Average Dividend ETF (DJD) Be on Your Investing Radar?

Style Box ETF report for DJD

DJD : 44.86 (-1.29%)
IBM : 146.18 (-1.48%)
MRK : 108.45 (+0.88%)
DOW : 50.20 (-2.64%)
SPY : 395.91 (-1.60%)
IVV : 397.69 (-1.58%)
3 Reasons Pfizer Stock Will Crush the Broader Market in 2023

Pfizer's revenue growth is far from over.

MRK : 108.45 (+0.88%)
ABBV : 158.43 (-0.75%)
MRNA : 175.38 (-0.58%)
PFE : 49.57 (+0.73%)
Factors That Make Elevance Health (ELV) a Lucrative Bet Now

Elevance Health (ELV) continues to benefit from sustained top-line growth, higher membership in Government business and a sturdy financial position.

MRK : 108.45 (+0.88%)
MEDP : 212.65 (-2.37%)
SWAV : 257.27 (-2.65%)
ELV : 512.78 (-0.21%)
3 Stocks Insiders Can’t Stop Buying This Month

After signs of cooling inflation, investors are hopeful that the Fed will slow its rate hikes over the coming months. With surging optimism, fundamentally strong stocks Merck (MRK), Coca-Cola (KO), and...

KO : 62.70 (+0.02%)
MRK : 108.45 (+0.88%)
VZ : 38.24 (-2.00%)
Should Value Investors Buy Innoviva (INVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

INVA : 12.91 (-1.00%)
MRK : 108.45 (+0.88%)
Merck & Co., Inc. (MRK) Hits Fresh High: Is There Still Room to Run?

Merck (MRK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

MRK : 108.45 (+0.88%)
2 Biotech Stocks You Can Buy and Hold for the Next Decade

These two companies are facing short-term issues that are likely to give way to long-term success.

BNTX : 161.49 (+4.29%)
MRK : 108.45 (+0.88%)
PFE : 49.57 (+0.73%)
MRVI : 14.37 (+0.49%)
DNA : 1.8400 (-7.54%)
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

AZN : 66.21 (+0.06%)
MRK : 108.45 (+0.88%)
ANGN : 0.8785 (-2.39%)
CLVS : 0.3399 (-1.76%)
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication

Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.

GSK : 33.76 (-0.68%)
MRK : 108.45 (+0.88%)
ABBV : 158.43 (-0.75%)
IMGO : 35.65 (-0.03%)
4 Stocks to Buy That Have Caught Wall Street's Attention

With strong indications of slowing interest rate hikes by the Fed poised to feed the stock market rally, it could be wise to invest in Merck (MRK), AT&T (T), Mosaic (MOS), and Photronics (PLAB), which...

MOS : 50.26 (-2.92%)
MRK : 108.45 (+0.88%)
PLAB : 18.65 (-0.21%)
T : 18.82 (-1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 110.97
2nd Resistance Point 109.93
1st Resistance Point 109.19
Last Price 108.45
1st Support Level 107.42
2nd Support Level 106.38
3rd Support Level 105.64

See More

52-Week High 108.90
Last Price 108.45
Fibonacci 61.8% 94.61
Fibonacci 50% 90.20
Fibonacci 38.2% 85.79
52-Week Low 71.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar